Patents by Inventor Cory Teuscher

Cory Teuscher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • p38 MAPK Pathway Inhibitors as Female-Specific Therapeutics
    Publication number: 20140127231
    Abstract: The present invention provides compositions and methods for preventing and treating a disorder, including, for example, an autoimmune disorder (e.g. multiple sclerosis), neuroinflammation, a neurodegenerative disease, or a behavioral disorder. In one embodiment, the present invention includes administering a p38 MAPK inhibitor to a female subject in order to treat or prevent an autoimmune disorder. In another embodiment, the invention provides administering a p38 MAPK inhibitor to a specific cell population.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 8, 2014
    Applicant: UNIVERSITY OF VERMONT
    Inventors: Cory Teuscher, Mercedes Rincon, Dimitry Krementsov, Rajkumar Noubade
  • Methods for predicting psychotropic drugs which elicit weight gain
    Patent number: 8148095
    Abstract: The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We found that orexigenic AAPDs potently and selectively activate hypothalamic AMP kinase (AMPK), an action abolished in mice with deletion of histamine H1 receptors. These findings afford a means of developing better therapeutic agents and provide insight into the hypothalamic regulation of food intake.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: April 3, 2012
    Assignees: The Johns Hopkins University, The University of Vermont College of Medicine
    Inventors: Solomon H. Snyder, Alex Huang, Cory Teuscher, Sangwon Kim
  • Methods for Predicting Psychotropic Drugs Which Elicit Weight Gain
    Publication number: 20090304596
    Abstract: The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We found that orexigenic AAPDs potently and selectively activate hypothalamic AMP kinase (AMPK), an action abolished in mice with deletion of histamine H1 receptors. These findings afford a means of developing better therapeutic agents and provide insight into the hypothalamic regulation of food intake.
    Type: Application
    Filed: September 10, 2007
    Publication date: December 10, 2009
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Solomon H. Snyder, Alex Huang, Cory Teuscher, Sangwon Kim